RxDoctor Payments DataLook up a doctor →

Mark Kontos, MD

Ophthalmology · Spokane Valley, WANPI 1114938990

Payments from drug & device makers

$177,411in general payments, 2019–2025

Across 406 payments — averaging $436.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$79K
  • Carl Zeiss Meditec, Inc.$28K
  • Rxsight Inc$16K
  • AbbVie$11K
  • Alcon$11K
  • Avedro Inc.$6K
  • plus $26K from 26 others

What the payments were for

  • Consulting fees$146,00983%
  • Speaking & faculty fees$7,0884%
  • Travel & lodging$3,3162%
  • Food & beverage$18,79111%
  • Gifts$190%
  • Entertainment$1180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$177,411 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$221,216
Medicare patients
439
Services billed
1,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost11$7,424
Prednisolone Acetate199$5,647
Ketorolac Tromethamine217$3,956
Ofloxacin171$1,957
Latanoprost139$1,202
Dorzolamide Hcl11$246
Timolol Maleate26$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$11,235$7,42411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →